MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530725 | Name: Mepiroxol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mepiroxol is a bioactive chemical.

Chemical Structure

Mepiroxol
Mepiroxol
CAS#6968-72-5

Theoretical Analysis

MedKoo Cat#: 530725

Name: Mepiroxol

CAS#: 6968-72-5

Chemical Formula: C6H7NO2

Exact Mass: 125.0477

Molecular Weight: 125.13

Elemental Analysis: C, 57.59; H, 5.64; N, 11.19; O, 25.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Mepiroxol
IUPAC/Chemical Name
3-Pyridinemethanol 1-oxide
InChi Key
LQYJAVWWKTWWKN-UHFFFAOYSA-N
InChi Code
InChI=1S/C6H7NO2/c8-5-6-2-1-3-7(9)4-6/h1-4,8H,5H2
SMILES Code
OCC1=C[N+]([O-])=CC=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 125.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Khomenko T, Deng X, Ahluwalia A, Tarnawski A, Patel KN, Sandor Z, Szabo S. STAT3 and importins are novel mediators of early molecular and cellular responses in experimental duodenal ulceration. Dig Dis Sci. 2014 Feb;59(2):297-306. doi: 10.1007/s10620-013-2807-6. Epub 2014 Jan 3. PubMed PMID: 24385009. 2: Satoh H. Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. Curr Pharm Des. 2013;19(1):67-75. Review. PubMed PMID: 22950496. 3: Rovira M, Huang W, Yusuff S, Shim JS, Ferrante AA, Liu JO, Parsons MJ. Chemical screen identifies FDA-approved drugs and target pathways that induce precocious pancreatic endocrine differentiation. Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19264-9. doi: 10.1073/pnas.1113081108. Epub 2011 Nov 14. PubMed PMID: 22084084; PubMed Central PMCID: PMC3228434. 4: Takara K, Hayashi R, Kokufu M, Yamamoto K, Kitada N, Ohnishi N, Yokoyama T. Effects of nonsteroidal anti-inflammatory drugs on the expression and function of P-glycoprotein/MDR1 in Caco-2 cells. Drug Chem Toxicol. 2009;32(4):332-7. doi: 10.1080/01480540903130658. PubMed PMID: 19793025. 5: Yang SJ, Katori M, Majima M. A novel model of pain sensation using superfused gastrosplenic omentum preparation of anesthetized rats. J Pharmacol Sci. 2008 Feb;106(2):249-56. Epub 2008 Feb 9. PubMed PMID: 18270472. 6: Tanaka J, Iida H, Abe M, Yuda Y, Inoue S, Okabe S. Gastric antisecretory and anti-ulcer effect of ME3407, a new benzimidazole derivative, in rats. Arzneimittelforschung. 2004;54(4):221-9. PubMed PMID: 15146935. 7: Escrivà E, García-Lozano J, Martínez-Lillo J, Nuñez H, Server-Carrió J, Soto L, Carrasco R, Cano J. Synthesis, crystal structure, magnetic properties, and theoretical studies of [(Cu(mepirizole)Br)2(mu-OH)(mu-pz)] (mepirizole=4-methoxy-2-(5-methoxy-3-methyl-1H-pyrazol-1-yl)-6-methylpyrimidine; pz=pyrazolate), a novel mu-pyrazolato-mu-hydroxo-dibridged copper(II) complex. Inorg Chem. 2003 Dec 15;42(25):8328-36. PubMed PMID: 14658885. 8: Lee CH, Cheng ST. Kikuchi-Fujimoto disease: a case report. Kaohsiung J Med Sci. 2003 May;19(5):246-51. PubMed PMID: 12822683. 9: Onoa GB, Moreno V. Study of the modifications caused by cisplatin, transplatin, and Pd(II) and Pt(II) mepirizole derivatives on pBR322 DNA by atomic force microscopy. Int J Pharm. 2002 Oct 1;245(1-2):55-65. PubMed PMID: 12270242. 10: Takeuchi K, Sugamoto S, Suzuki K, Kawauchi S, Furukawa O. Effects of endothelin-1 on duodenal bicarbonate secretion and mucosal integrity in rats. Chin J Physiol. 1999 Sep 30;42(3):129-35. PubMed PMID: 10707886. 11: Sohn SK, Chang MS, Choi WS, Kim KB, Woo TW, Lee SB, Chung YK. Biochemical and pharmacological characteristics of a newly synthesized H+-K+ ATPase inhibitor, YJA20379-1, 2-amino-4,5-dihydro-8-phenylimidazole[2,1-b]thiazolo[5,4-g]benzothiazol e. Can J Physiol Pharmacol. 1999 May;77(5):330-8. PubMed PMID: 10535682. 12: Onoa GB, Moreno V, Font-Bardia M, Solans X, Pérez JM, Alonso C. Structural and cytotoxic study of new Pt(II) and Pd(II) complexes with the bi-heterocyclic ligand mepirizole. J Inorg Biochem. 1999 Jun 30;75(3):205-12. PubMed PMID: 10474205. 13: Uchiyama K, Wakatsuki D, Kakinoki B, Takeuchi Y, Araki T, Morinaka Y. Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Methods Find Exp Clin Pharmacol. 1999 Mar;21(2):115-22. PubMed PMID: 10327392. 14: Takeuchi K, Konaka A, Nishijima M, Kato S, Yasuhiro T. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7. PubMed PMID: 10197495. 15: Chung YK, Chang MS, Kim KB, Sohn SK, Woo TW, Lee SB, Choi WS. The biochemical and pharmacological properties of a newly synthesized H+-K+ ATPase inhibitor, 2-dimethylamino-4,5-dihydrothiazolo[4,5:3,4]pyridol-[1,2-a]benzimidazol e. Can J Physiol Pharmacol. 1998 Sep;76(9):921-9. PubMed PMID: 10066143. 16: Takeuchi K, Hirata T, Yamamoto H, Kunikata T, Ishikawa M, Ishihara Y. Effects of S-0509, a novel CCKB/gastrin receptor antagonist, on acid secretion and experimental duodenal ulcers in rats. Aliment Pharmacol Ther. 1999 Jan;13(1):87-96. PubMed PMID: 9892884. 17: Sohn SK, Chang MS, Chung YK, Kim KB, Wook TW, Kim SG, Choi WS. Biochemical and pharmacological properties of a new proton pump inhibitor, 2-amino-4,5-dihydropyrido[1,2-a]thiazolo [5,4-g] benzimidazole (YJA20379-5). Arch Pharm Res. 1998 Jun;21(3):241-7. PubMed PMID: 9875438. 18: Iinuma S, Yoshikawa T, Yoshida N, Naito Y, Kondo M. Role of active oxygen species and lipid peroxidation in mepirizole-induced duodenal ulcers in rats. Dig Dis Sci. 1998 Aug;43(8):1657-64. PubMed PMID: 9724147. 19: Yagi K, Takehara K, Kitamura M, Takeuchi K. Effects of pituitary adenylate cyclase activating polypeptide-27 on alkaline secretory and mucosal ulcerogenic responses in rat duodenum. Life Sci. 1998;63(5):317-25. PubMed PMID: 9714419. 20: Kim KB, Chang MS, Chung YK, Sohn SK, Kim SG, Choi WS. Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[(2-thiophenyl)amino]quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats. J Pharm Pharmacol. 1998 May;50(5):521-9. PubMed PMID: 9643446.